Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano – 23 June 2010 – Nonalcoholic fatty liver disease (NAFLD) encompasses a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH). NAFLD carries a higher risk of cardio‐metabolic and liver‐related complications, the latter being confined to NASH and demanding specific treatment. We assessed the efficacy of proposed treatments for NAFLD/NASH by reviewing reports of randomized controlled trials (RCTs) on online databases and national and international meeting abstracts through January 2010.

Roberto J. Groszmann – 23 June 2010

Kui Wang, Jian Liu, Zhen‐Lin Yan, Jun Li, Le‐Hua Shi, Wen‐Ming Cong, Yong Xia, Qi‐Fei Zou, Tao Xi, Feng Shen, Hong‐Yang Wang, Meng‐Chao Wu – 23 June 2010 – The association between the overexpression of aspartyl‐(asparaginyl)‐β‐hydroxylase (AAH) and the invasiveness of hepatocellular carcinoma (HCC) in vitro has been reported. However, the prognostic value of AAH expression in HCC remains unclear. The purpose of this study was to investigate the relationship between AAH expression, tumor recurrence, and patient survival.

Sanjay Y. Bangarulingam, Einar Björnsson, Felicity Enders, Emily G. Barr Fritcher, Gregory Gores, Kevin C. Halling, Keith D. Lindor – 23 June 2010

Jessica A. Davila, Robert O. Morgan, Peter A. Richardson, Xianglin L. Du, Katherine A. McGlynn, Hashem B. El‐Serag – 23 June 2010 – Surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is recommended but may not be performed. The extent and determinants of HCC surveillance are unknown. We conducted a population‐based United States cohort study of patients over 65 years of age to examine use and determinants of prediagnosis surveillance in patients with HCC who were previously diagnosed with cirrhosis.

Weici Zhang, Masanobu Tsuda, Guo‐Xiang Yang, Koichi Tsuneyama, Guanghua Rong, William M. Ridgway, Aftab A. Ansari, Richard A. Flavell, Ross L. Coppel, Zhe‐Xiong Lian, M. Eric Gershwin – 23 June 2010 – The role of interleukin‐6 (IL‐6) in autoimmunity attracts attention because of the clinical usage of monoclonal antibodies to IL‐6 receptor (IL‐6R), designed to block IL‐6 pathways.

Khoa D. Lam, Peter Bacchetti, Fahim Abbasi, Claudia E. Ayala, Samuel M. Loeb, Vidhi Shah, Michael J. Wen, Gerald M. Reaven, Jacquelyn J. Maher, Mandana Khalili – 23 June 2010 – Studies using surrogate estimates show high prevalence of insulin resistance in hepatitis C infection. This study prospectively evaluated the correlation between surrogate and directly measured estimates of insulin resistance and the impact of obesity and ethnicity on this relationship.

David A. Shafritz – 23 June 2010

Darrell H. G. Crawford, Linda M. Fletcher, Katherine A. Stuart – 23 June 2010

Stuart F. W. Kendrick, Elsbeth Henderson, Jeremy Palmer, David E. J. Jones, Chris P. Day – 23 June 2010 – Corticosteroid therapy has shown some benefit in severe acute alcoholic hepatitis (AAH); however, this is limited by uncertainty in patient selection and variable clinical response. Theophylline has been shown to ameliorate impaired steroid sensitivity in chronic obstructive pulmonary disease by facilitating corticosteroid‐induced silencing of proinflammatory genes.